Urothelial Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Recruiting
  • Carcinoma, Transitional Cell
  • +6 more
  • enfortumab vedotin (EV)
  • +4 more
  • Anchorage, Alaska
  • +105 more
2022-04-06
Apr 6, 2022
N
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Recruiting
  • Bladder Cancer
  • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    N
    Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
    Recruiting
    • Urothelial Carcinoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    N
    A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
    Not yet recruiting
    • Urothelial Cancer
    • +4 more
      • Washington, District of Columbia
      • +2 more
      2022-04-07
      Apr 7, 2022
      N
      Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
      Recruiting
      • Urothelial Cancer
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      P
      Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
      Recruiting
      • Advanced Malignancies
      • +4 more
      • Chermside, Queensland, Australia
      • +10 more
      2022-04-04
      Apr 4, 2022
      A
      A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
      Active, not recruiting
      Has Results
      • Ureteral Cancer
      • +2 more
      • Enfortumab Vedotin
      • +3 more
      • Orange, California
      • +157 more
      2022-03-29
      Mar 29, 2022
      A
      Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
      Recruiting
      • Urothelial Cancer
      • Enfortumab vedotin
      • +4 more
      • Chandler, Arizona
      • +189 more
      2022-03-28
      Mar 28, 2022
      N
      T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive - 2021
      Completed
      Has Results
      • Cervical Cancer
      • +4 more
      • Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
      • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-03-02
      Mar 2, 2022
      J
      An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
      Recruiting
      • Urothelial Cancer
      • Scottsdale, Arizona
      • +160 more
      2022-03-24
      Mar 24, 2022
      I
      Study of INCB086550 in Select Solid Tumors
      Active, not recruiting
      • Non Small Cell Lung Cancer
      • +4 more
      • Plovdiv, Bulgaria
      • +11 more
      2022-03-24
      Mar 24, 2022
      J
      A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
      Recruiting
      • Urothelial Cancer
      • Receptors, Fibroblast Growth Factor
      • Archival Tumor Tissue Sample
      • Tucson, Arizona
      • +220 more
      2022-03-24
      Mar 24, 2022
      J
      A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
      Recruiting
      • Urothelial Cancer
      • Anchorage, Alaska
      • +414 more
      2022-03-24
      Mar 24, 2022
      A
      Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
      Active, not recruiting
      Has Results
      • Urothelial Cancer
      • MEDI4736 (Durvalumab)
      • +4 more
      • Los Angeles, California
      • +221 more
      2022-03-22
      Mar 22, 2022
      N
      A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma - 2021
      Terminated
      Has Results
      • Urothelial Cancer
      • Bintrafusp alfa (M7824)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-02-25
      Feb 25, 2022
      P
      Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
      Recruiting
      • Squamous Cell Carcinoma of the Head and Neck
      • +10 more
      • Scottsdale, Arizona
      • +31 more
      2022-03-18
      Mar 18, 2022
      B
      Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
      Recruiting
      • Urothelial Cancer
      • Nivolumab
      • +4 more
      • Birmingham, Alabama
      • +196 more
      2022-03-17
      Mar 17, 2022
      N
      A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
      Recruiting
      • NSCLC, Non Small Cell Lung Cancer
      • +9 more
      • Santa Monica, California
      • +22 more
      2022-03-18
      Mar 18, 2022
      I
      Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
      Recruiting
      • Urothelial Cancer
      • Metastatic Solid Tumor
      • New York, New York
        Icahn School of Medicine at Mount Sinai
      2022-03-05
      Mar 5, 2022
      S
      Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer
      Not yet recruiting
      • Urothelial Cancer
      • Huelva, Andalucia, Spain
      • +11 more
      2022-03-09
      Mar 9, 2022
      M
      Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) - 2022
      Completed
      Has Results
      • Urothelial Cancer
      • pembrolizumab
      • (no location specified)
      2022-02-24
      Feb 24, 2022
      P
      PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
      Recruiting
      • Advanced Solid Tumors
      • +5 more
      • Grand Rapids, Michigan
      • +4 more
      2022-03-03
      Mar 3, 2022
      D
      Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
      Recruiting
      • Melanoma
      • +7 more
      • Nivolumab or Pembrolizumab (dependent upon approved indication)
      • +2 more
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      2022-02-10
      Feb 10, 2022
      F
      Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
      Recruiting
      • Urothelial Cancer
      • Niraparib plus Cabozantinib
      • Barcelona, Cataluña, Spain
      • +10 more
      2022-02-08
      Feb 8, 2022
      E
      Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery
      Active, not recruiting
      • Urothelial Cancer
      • Bergamo, Italy
      • +4 more
      2022-01-25
      Jan 25, 2022